Moreover, HSP90 inhibitor therapy may work as indirect “immune adjuvant” leading to increased therapeutic T cell recruitment against EphA2 expressing tumors, such as BRAFi-resistant melanoma, due to transient proteasome-dependent degradation of HSP90 client protein EphA2 in absence of the functional chaperone [99,100]. The gene discussed is EPHA2; the disease is melanoma.